Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab + GEMOX for Biliary Tract Cancer
NCT07854600Phase 2Recruiting
- Sponsor
- Purinomia Biotech
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in biliary tract cancer (BTC), sponsored by Purinomia Biotech. Primary endpoints: R0 Resection Rate and Objective Response Rate at 24 weeks. Started Oct 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07854600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07854600.